Key Quantitative Figures

Consolidated Financial Results (Q2 FY27):

  • Revenue from operations: ₹192.33 crore
  • Other income: ₹8.94 crore
  • Total income: ₹201.27 crore
  • Total expenses: ₹153.69 crore
  • Profit before tax: ₹47.58 crore
  • Tax expense: ₹10.98 crore
  • Net profit after tax: ₹36.60 crore
  • Basic EPS: ₹8.85
  • Diluted EPS: ₹8.82

Consolidated Financial Results (H1 FY27):

  • Revenue from operations: ₹372.54 crore
  • Other income: ₹11.75 crore
  • Total income: ₹384.29 crore
  • Total expenses: ₹297.25 crore
  • Profit before tax: ₹87.04 crore
  • Tax expense: ₹19.99 crore
  • Net profit after tax: ₹67.05 crore
  • Basic EPS: ₹15.25
  • Diluted EPS: ₹15.20

Standalone Financial Results (Q2 FY27):

  • Revenue from operations: ₹35.65 crore
  • Other income: ₹14.76 crore
  • Total income: ₹50.41 crore
  • Total expenses: ₹40.74 crore
  • Profit before tax: ₹9.67 crore
  • Tax expense: ₹1.95 crore
  • Net profit after tax: ₹7.72 crore
  • Basic EPS: ₹1.68
  • Diluted EPS: ₹1.67

Standalone Financial Results (H1 FY27):

  • Revenue from operations: ₹62.64 crore
  • Other income: ₹24.31 crore
  • Total income: ₹86.95 crore
  • Total expenses: ₹75.89 crore
  • Profit before tax: ₹11.06 crore
  • Tax expense: ₹2.31 crore
  • Net profit after tax: ₹8.75 crore
  • Basic EPS: ₹1.90
  • Diluted EPS: ₹1.89

Dates of Action

  • Board meeting held: October 29, 2026 (12:00 PM to 1:30 PM IST)
  • Financial period ended: September 30, 2026
  • Auditor appointment date: October 29, 2026 (effective from FY27 to FY31)

Parties Involved

  • Statutory Auditors: M/s. Pankaj R. Shah and Associates (existing), M/s Talati and Talati LLP (new joint appointment)
  • Subsidiaries included in consolidation: Senores Pharmaceuticals Inc, Ratnatris Pharmaceuticals Private Limited, Havix Group Inc, Apnar Pharma Private Limited, 9488 Jackson Trail LLC, Zoraya Pharmaceuticals LLC, Amerisyn LLC

Financial Impact

Consolidated Balance Sheet (as of September 30, 2026):

  • Total assets: ₹1,680.60 crore
  • Total equity: ₹1,031.53 crore
  • Non-current liabilities: ₹237.48 crore
  • Current liabilities: ₹411.59 crore
  • Cash and cash equivalents: ₹17.96 crore

Consolidated Cash Flows (H1 FY27):

  • Cash from operating activities: ₹29.22 crore
  • Cash used in investing activities: ₹112.18 crore
  • Cash from financing activities: ₹55.36 crore
  • Net decrease in cash: ₹27.59 crore

Capital Structure Impact

  • Paid-up equity share capital: ₹46.05 crore (face value ₹10 per share)
  • 11,70,000 warrants allotted to Promoter and Promoter Group on preferential basis (March 28, 2026) at issue price of ₹812 per warrant
  • ₹23.75 crore received as minimum upfront subscription amount (25% of issue price)

IPO Proceeds Utilization (as of September 30, 2026):

  • Total IPO proceeds: ₹500.00 crore
  • Amount utilized: ₹418.83 crore
  • Amount unutilized: ₹81.17 crore
  • Unutilized amount parked as fixed deposit with ICICI Bank (₹81.11 crore) and HDFC bank account (₹0.06 crore)

Management Commentary

From media release: Company delivered 9th consecutive quarter of healthy double-digit growth. Regulated Markets business sustained strong momentum with ANDA portfolio nearly doubling to 64 (23 commercialized products, 41 planned launches). Guidance maintained for FY27: 30-40% revenue growth and 50-60% PAT growth, followed by anticipated annual growth of 20-25% over next two years.

Auditor Emphasis of Matter

Tax Provisions and Deferred Tax have been determined as estimated by the management solely. Auditor conclusion not modified in respect of these matters.

Additional Information

  • Company operates in single segment: Pharmaceuticals
  • Previous period figures have been regrouped/rearranged for comparability
  • Documents uploaded on company website: www.senorespharma.com